Eating a ketogenic diet — one low in carbohydrates and high in fats — led to less fatigue and depression for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial that was designed to assess the tolerability of the dietary intervention. Measures of disability and quality of life also improved during the study while participants…
Category: Uncategorised
NfL test for multiple sclerosis
Quanterix Granted Breakthrough Device Designation from U.S. FDA Blood-based assay has the potential to serve the multiple sclerosis (MS) community in management of relapsing-remitting form of the disease April 22, 2022 08:30 AM Eastern Daylight Time: Quanterix Corporation, a company digitising biomarker analysis with the goal of advancing the science of precision health, announced that…
Using telemedicine in neuro-oncology – practical guidance
The COVID-19 pandemic has ensured the expansion of telemedicine into nearly every medical specialty. This article summarises current practice and makes recommendations for integrating virtual care in the practice of neuro-oncology. It identifies current telemedicine practice, provides practical guidance for conducting telemedicine visits, and generates recommendations for integrating virtual care into neuro-oncology practice. Practical aspects…
Study links gut microbiota strains with more severe strokes and poorer post-stroke recovery
A new study has identified strains of gut microbiota that are associated with more severe strokes and worse post-stroke recovery, revealing that the gut microbiome could be an important factor in stroke risk and outcomes1. The study, presented 28 April 2022 at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated…
Pregabalin may slightly increase risk of major congenital malformations
20 April 2022: The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update on the use of pregabalin in pregnancy, after a new study suggests that it may slightly increase the risk of major congenital malformations. Advice for healthcare professionals is that potentially fertile women should continue to use effective contraception…
US approval for ULTOMIRIS® for gMG
ULTOMIRIS® (ravulizumab-cwvz) approved in the US for Adults with Generalised Myasthenia Gravis First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalised myasthenia gravis ULTOMIRIS showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks April 28, 2022:…
ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results Results demonstrate safety and efficacy of ZTALMY, first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients two years and older Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of therapeutics to treat seizure disorders, announced on…
Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease
Abstract of poster presented at the AAN 2022, by Michele Tagliati, MD, FAAN Treatment with liraglutide improves critical features of PD, including non-motor symptoms and activities of daily living. These results validate similar outcomes reported with other GLP-1 agonists in PD and offer new strategies to treat the constellation of PD symptoms. BackgroundInsulin resistance (IR)…
Benefits of Ocrelizumab in SPMS and PPMS
New Data for Genentech’s Ocrevus (ocrelizumab) show benefit in disability progression and cognitive decline in both Secondary Progressive and Primary Progressive Multiple Sclerosis – 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – 70% of…
